Pay in 4 interest-free payments of $7.45 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
GLP-1 RA treatment in Parkinsons Disease and Alzheimers Disease)
By Lana Pine | Published on December 17, 2025 4 min read A large real-world study published in Neurology found that people with Type 2 diabetes taking glucagon-like peptide-1 (GLP-1) receptor agonists had a lower risk of developing epilepsy than those taking dipeptidyl peptidase-4 (DPP-4) inhibitors
The options are available
No evidence of hormonal, hepatic, or systemic adverse effects has been observed in available research data
ANALYZE MY TRT Personalized analysis
US$ 29.38
US$ 26.16
US$ 21.13
US$ 28.65
US$ 21.12
